Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day
This was the stock's second consecutive day of gains.
BioPharma Dive17h
GSK’s 5-in-1 meningococcal shot wins FDA approval
Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...
MyChesCo on MSN4d
INOVIO’s INO-3107 Shows Powerful Potential for Treating Recurrent Respiratory Papillomatosis
INOVIO (NASDAQ: INO) has unveiled promising peer-reviewed results from its Phase 1/2 clinical trial for INO-3107, a ...
Longwood Fund launches anxiety drug developer with $93.5M investment
A Boston VC firm is launching a new neuroscience company with a $93M investment that aims to treat disorders including ...
INO-3107 shows promise in reducing surgeries for RRP patients
PLYMOUTH MEETING, Pa. - INOVIO (NASDAQ: INO), a biotechnology company with a market capitalization of approximately $69 million, has announced positive results from a Phase 1/2 clinical trial of ...